Silybin and its new congeners - possibilities in the adjuvant cancer treatment
Public support
Provider
Ministry of Education, Youth and Sports
Programme
KONTAKT II
Call for proposals
KONTAKT II 3 (SMSM2013LH3)
Main participants
Mikrobiologický ústav AV ČR, v. v. i.
Contest type
VS - Public tender
Contract ID
MSMT-16744/2013
Alternative language
Project name in Czech
Silybin a jeho nové kongenery ? možnosti ve využití v adjuvantní léčbě nádorových onemocnění
Annotation in Czech
Bude vyvinuta metoda pro přípravu opticky čistého silychristinu v preparativním měřítku. Budou připraveny nové deriváty silychristinu a silybinu pro následné testování na protinádorovou aktivitu a pro adjuvantní léčbu nádorových onemocnění.
Scientific branches
R&D category
ZV - Basic research
CEP classification - main branch
FR - Pharmacology and apothecary chemistry
CEP - secondary branch
CC - Organic chemistry
CEP - another secondary branch
EI - Biotechnology and bionics
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
10401 - Organic chemistry<br>20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30104 - Pharmacology and pharmacy<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
New anticancer derivatives of silybin and silychristin were found and their pharmacological properties were investigated in detail. Reactivity of silychristin was investigated in detail and a complex set of protection/deprotection methods was elaborated.
Solution timeline
Realization period - beginning
Mar 1, 2013
Realization period - end
Dec 31, 2015
Project status
U - Finished project
Latest support payment
Feb 27, 2015
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP16-MSM-LH-U/01:1
Data delivery date
Oct 9, 2017
Finance
Total approved costs
1,796 thou. CZK
Public financial support
1,796 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK